roferon-a solution inj 36000000unit/ml
hoffmann-la roche limited - interferon alpha-2a - solution - 36000000unit - interferon alpha-2a 36000000unit - antineoplastic agents
roferon-a solution inj. 9million i.u./0.9ml
hoffmann-la roche limited - interferon alpha-2a - solution - 9000000unit - interferon alpha-2a 9000000unit - antineoplastic agents
roferon-a soln-liq im sc 4.5million i.u/ml liquid
hoffmann-la roche limited - interferon alpha-2a - liquid - 4.5m - interferon alpha-2a 4.5m - antineoplastic agents
roferon-a solution 6 million i.u./ml
hoffmann-la roche limited - interferon alpha-2a - solution - 6m - interferon alpha-2a 6m - antineoplastic agents
rebif 44 interferon beta-1a (rch) 132 microgram/1.5ml solution for injection multidose cartridge
merck healthcare pty ltd - interferon beta-1a, quantity: 88 microgram/ml - injection, solution - excipient ingredients: methionine; acetic acid; mannitol; poloxamer; water for injections; benzyl alcohol; sodium hydroxide - rebif is indicated for the treatment of: ? patients with a single demyelinating event in the central nervous system with an active inflammatory process, if alternative diagnoses have been excluded, and if they are determined to be at high risk of developing clinically definite multiple sclerosis. high risk can be inferred from cerebral mri with 2 or more lesions suggestive of demyelination.,? ambulatory patients with multiple sclerosis who have experienced two or more relapses within the last 2 years. rebif therapy should not be initiated in secondary progressive ms patients who no longer experience relapses.?
rebif 44 interferon beta-1a (rch) 44 microgram/0.5ml injection pre-filled syringe
merck healthcare pty ltd - interferon beta-1a, quantity: 88 microgram/ml - injection, solution - excipient ingredients: benzyl alcohol; water for injections; sodium hydroxide; acetic acid; methionine; poloxamer; mannitol - rebif is indicated for the treatment of: ? patients with a single demyelinating event in the central nervous system with an active inflammatory process, if alternative diagnoses have been excluded, and if they are determined to be at high risk of developing clinically definite multiple sclerosis. high risk can be inferred from cerebral mri with 2 or more lesions suggestive of demyelination.,? ambulatory patients with multiple sclerosis who have experienced two or more relapses within the last 2 years. rebif therapy should not be initiated in secondary progressive ms patients who no longer experience relapses.?
rebif 44 interferon beta-1a (rch) 44 microgram/0.5ml injection pre-filled syringe autoinjector
merck healthcare pty ltd - interferon beta-1a, quantity: 88 microgram/ml - injection, solution - excipient ingredients: benzyl alcohol; water for injections; sodium hydroxide; acetic acid; methionine; poloxamer; mannitol - rebif is indicated for the treatment of: ? patients with a single demyelinating event in the central nervous system with an active inflammatory process, if alternative diagnoses have been excluded, and if they are determined to be at high risk of developing clinically definite multiple sclerosis. high risk can be inferred from cerebral mri with 2 or more lesions suggestive of demyelination.,? ambulatory patients with multiple sclerosis who have experienced two or more relapses within the last 2 years. rebif therapy should not be initiated in secondary progressive ms patients who no longer experience relapses.?
roferon-a solution for injection 3million iu
cherubino limited delf building, sliema road, gzira, gzr 1637, malta - interferon alfa - solution for injection in a pre-filled syringe - interferon alfa-2a 3 million iu - immunostimulants
roferon-a 3 million international units (iu) solution for injection in pre-filled syringe
central procurement & supplies unit ub002 industrial estate, san gwann sgn 3000, malta - interferon alfa - solution for injection in a pre-filled syringe - interferon alfa-2a 3 million iu - immunostimulants
roferon-a
roche products (nz) ltd - interferon alfa-2a 18 miu - powder for injection - 18 miu - active: interferon alfa-2a 18 miu excipient: albumin sodium chloride water for injection